Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Zynga Inc is an electronic gaming & multimedia business based in the US. Zynga shares (ZNGA) are listed on the NASDAQ and all prices are listed in US Dollars. Zynga employs 2,245 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$7.65|
|52-week range||$7.55 - $12.32|
|50-day moving average||$8.34|
|200-day moving average||$9.92|
|Wall St. target price||$12.09|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.16|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-17)||-4.49%|
|1 month (2021-08-25)||-11.66%|
|3 months (2021-06-25)||-28.17%|
|6 months (2021-03-25)||-22.10%|
|1 year (2020-09-25)||-14.62%|
|2 years (2019-09-25)||26.66%|
|3 years (2018-09-25)||92.70%|
|5 years (2016-09-23)||169.37%|
Valuing Zynga stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Zynga's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Zynga's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.28. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Zynga's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Zynga's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $532.8 million.
The EBITDA is a measure of a Zynga's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$2.5 billion|
|Operating margin TTM||12.54%|
|Gross profit TTM||$1.2 billion|
|Return on assets TTM||4.02%|
|Return on equity TTM||-7.16%|
|Market capitalisation||$8.4 billion|
TTM: trailing 12 months
There are currently 69.3 million Zynga shares held short by investors – that's known as Zynga's "short interest". This figure is 5.2% down from 73.2 million last month.
There are a few different ways that this level of interest in shorting Zynga shares can be evaluated.
Zynga's "short interest ratio" (SIR) is the quantity of Zynga shares currently shorted divided by the average quantity of Zynga shares traded daily (recently around 27.9 million). Zynga's SIR currently stands at 2.48. In other words for every 100,000 Zynga shares traded daily on the market, roughly 2480 shares are currently held short.
However Zynga's short interest can also be evaluated against the total number of Zynga shares, or, against the total number of tradable Zynga shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zynga's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Zynga shares in existence, roughly 60 shares are currently held short) or 0.0674% of the tradable shares (for every 100,000 tradable Zynga shares, roughly 67 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Zynga.
Find out more about how you can short Zynga stock.
We're not expecting Zynga to pay a dividend over the next 12 months.
Over the last 12 months, Zynga's shares have ranged in value from as little as $7.55 up to $12.32. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Zynga's is 0.0191. This would suggest that Zynga's shares are less volatile than average (for this exchange).
Zynga Inc. provides social game services in the United States and internationally. The company develops, markets, and operates social games as live services played on mobile platforms, such as Apple iOS and Google's Android operating systems; social networking platforms, such as Facebook and Snapchat; and personal computers consoles, such as Nintendo's Switch game console, and other platforms and consoles. It also provides advertising services comprising mobile advertisements, engagement advertisements and offers, and branded virtual items and sponsorships for marketers and advertisers; and licenses its own brands. The company was formerly known as Zynga Game Network Inc. and changed its name to Zynga Inc. in November 2010.
Everything we know about the Enfusion IPO, plus information on how to buy in.
Everything we know about the Intuity Medical IPO, plus information on how to buy in.
Everything we know about the Pyxis Oncology IPO, plus information on how to buy in.
Everything we know about the AEON Biopharma IPO, plus information on how to buy in.
Everything we know about the IHS Holding Ltd IPO, plus information on how to buy in.
Everything we know about the BT Brands IPO, plus information on how to buy in.
Everything we know about the Immix IPO, plus information on how to buy in.
Everything we know about the Keter Group SA IPO, plus information on how to buy in.
Everything we know about the Theseus Pharmaceuticals IPO, plus information on how to buy in.
Everything we know about the MiNK Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.